Literature DB >> 25469523

GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.

Sharon L Karmon1, Hiroshi Mohri, William Spreen, Martin Markowitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25469523      PMCID： PMC4439214          DOI： 10.1097/QAI.0000000000000469

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  13 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.

Authors:  Elizabeth C Reuman; Michael H Bachmann; Vici Varghese; W Jeffrey Fessel; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

3.  A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.

Authors:  Martin Markowitz; Teresa H Evering; Donald Garmon; Marina Caskey; Melissa La Mar; Kristina Rodriguez; Vincent Sahi; Sarah Palmer; Nicole Prada; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

4.  FDA approves first drug to prevent HIV infection.

Authors:  Bob Roehr
Journal:  BMJ       Date:  2012-07-17

5.  Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1.

Authors:  Kevin D Mohammed; Michael B Topper; Mark A Muesing
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 6.  Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

7.  Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Authors:  Chasity D Andrews; William R Spreen; Hiroshi Mohri; Lee Moss; Susan Ford; Agegnehu Gettie; Kasi Russell-Lodrigue; Rudolf P Bohm; Cecilia Cheng-Mayer; Zhi Hong; Martin Markowitz; David D Ho
Journal:  Science       Date:  2014-03-04       Impact factor: 47.728

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

Review 10.  Long-acting injectable antiretrovirals for HIV treatment and prevention.

Authors:  William R Spreen; David A Margolis; John C Pottage
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283
View more
  12 in total

1.  Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

Authors:  Ujjwal Neogi; Kamalendra Singh; Shambhu G Aralaguppe; Leonard C Rogers; Duncan T Njenda; Stefan G Sarafianos; Bo Hejdeman; Anders Sönnerborg
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

Review 2.  Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Authors:  Walter Dehority; Jacobo Abadi; Andrew Wiznia; Rolando M Viani
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

3.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Authors:  Amy G Cutrell; Jonathan M Schapiro; Carlo F Perno; Daniel R Kuritzkes; Romina Quercia; Parul Patel; Joseph W Polli; David Dorey; Yongwei Wang; Sterling Wu; Veerle Van Eygen; Herta Crauwels; Susan L Ford; Mark Baker; Christine L Talarico; Marty St Clair; Jerry Jeffrey; C Thomas White; Simon Vanveggel; Kati Vandermeulen; David A Margolis; Michael Aboud; William R Spreen; Jan van Lunzen
Journal:  AIDS       Date:  2021-07-15       Impact factor: 4.632

Review 5.  Long-acting injectable cabotegravir for the prevention of HIV infection.

Authors:  Meredith E Clement; Ryan Kofron; Raphael J Landovitz
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

Review 6.  Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.

Authors:  Thomas Whitfield; Adele Torkington; Clare van Halsema
Journal:  HIV AIDS (Auckl)       Date:  2016-10-14

7.  Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.

Authors:  Jessica Radzio-Basu; Olivia Council; Mian-Er Cong; Susan Ruone; Alicia Newton; Xierong Wei; James Mitchell; Shanon Ellis; Christos J Petropoulos; Wei Huang; William Spreen; Walid Heneine; J Gerardo García-Lerma
Journal:  Nat Commun       Date:  2019-05-01       Impact factor: 14.919

8.  Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.

Authors:  Scott L Letendre; Anthony Mills; Debbie Hagins; Susan Swindells; Franco Felizarta; Jerome Devente; Christopher Bettacchi; Yu Lou; Susan Ford; Kenneth Sutton; Jafar Sadik Shaik; Herta Crauwels; Ronald D'Amico; Parul Patel
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

9.  Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.

Authors:  Tian Zhou; Hang Su; Prasanta Dash; Zhiyi Lin; Bhagya Laxmi Dyavar Shetty; Ted Kocher; Adam Szlachetka; Benjamin Lamberty; Howard S Fox; Larisa Poluektova; Santhi Gorantla; JoEllyn McMillan; Nagsen Gautam; R Lee Mosley; Yazen Alnouti; Benson Edagwa; Howard E Gendelman
Journal:  Biomaterials       Date:  2017-10-15       Impact factor: 12.479

10.  Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.

Authors:  Herana Kamal Seneviratne; Allyson N Hamlin; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Irene Kuo; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Adeola Adeyeye; Alex R Rinehart; Marybeth McCauley; Joseph S Eron; Myron S Cohen; Raphael J Landovitz; Craig W Hendrix; Namandjé N Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.